Development of a 89Zr radiolabeled anti-CD33 antibody for PET imaging of Acute Myeloid Leukemia

被引：0
|
作者：
Buckway, Brandon [1 ]
Burrell, Lance [2 ]
Shami, Paul [2 ]
Kosak, Ken [2 ]
Lum, David [2 ]
Yap, Jeffrey [1 ]
机构：
[1] Huntsman Canc Inst, Ctr Quantitat Canc Imaging, Salt Lake City, UT USA
[2] Huntsman Canc Inst, Salt Lake City, UT USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2020年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1053
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Treatment of patients with relapsed or refractory acute myeloid leukemia (AML) with recombinant engineered human anti-CD33 antibody-calicheamicin drug conjugate
    Sievers, EL
    Bernstein, ID
    Spielberger, RT
    Forman, SJ
    ShannonDorcy, K
    Appelbaum, FR
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 398 - 398
  • [32] anti-CD33 antibodies radiolabeled with thorium-226 or bismuth-213 break chemo- and radioresistance in myeloid leukemia cells
    Friesen, C.
    Roscher, M.
    Hormann, I.
    Morgenstern, A.
    Bruchertseifer, F.
    Simonelli, F.
    Apostolidis, C.
    Miltner, E.
    ONKOLOGIE, 2010, 33 : 177 - 177
  • [33] Optimization of 89Zr PET imaging using both phantom and clinical studies with [89Zr]-Df-IAB22M2C, an anti-CD8 minibody
    Daube-Witherspoon, Margaret
    Farwell, Michael
    Sunderland, John
    Viswanath, Varsha
    Korn, Ronald
    Wilson, Ian
    Karp, Joel
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
  • [34] Monocyte-mediated lysis of acute myeloid leukemia cells in the presence of the bispecific antibody 251x22 (Anti-CD33 x Anti-CD64)
    Chen, J
    Zhou, JH
    Ball, ED
    CLINICAL CANCER RESEARCH, 1995, 1 (11) : 1319 - 1325
  • [35] Development of Anti-CD44 Therapeutic Antibody for Acute Myeloid Leukemia
    Zhang Tao
    Qu Hao
    Zhang Li-Yan
    Zhang Yi
    Wang Mei
    Wang Dong-Mei
    He Da-Shui
    Huang Li-Hua
    Zhu Wei-Bin
    Zhang Yu-Guang
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2009, 36 (02) : 190 - 197
  • [36] Evaluating immune checkpoint blockade treatment efficacy via [89Zr]-CD4 and [89Zr]-CD8 PET imaging in breast cancer mouse models
    Lu, Yun
    Houson, Hailey
    Mascioni, Alessandro
    Jia, Fang
    Song, Patrick N.
    Napier, Tiara
    Mansur, Amer M.
    Gallegos, Carlos A.
    Larimer, Benjamin M.
    Lapi, Suzanne E.
    Sorace, Anna G.
    CANCER RESEARCH, 2022, 82 (12)
  • [37] Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia
    Simona Lapusan
    Maria B. Vidriales
    Xavier Thomas
    Stephane de Botton
    Anne Vekhoff
    Ruoping Tang
    Charles Dumontet
    Rodica Morariu-Zamfir
    John M. Lambert
    Marie-Laure Ozoux
    Philippe Poncelet
    Jesus F. San Miguel
    Ollivier Legrand
    Daniel J. DeAngelo
    Francis J. Giles
    Jean-Pierre Marie
    Investigational New Drugs, 2012, 30 : 1121 - 1131
  • [38] Direct effect of bispecific anti-CD33 x anti-CD64 antibody on proliferation and signaling in myeloid cells
    Balaian, L
    Ball, ED
    LEUKEMIA RESEARCH, 2001, 25 (12) : 1115 - 1125
  • [39] Sequential cytarabine and α-particle immunotherapy with Bismuth-213-labeled anti-CD33 monoclonal antibody HuM195 in acute myeloid leukemia (AML).
    Burke, JM
    Jurcic, JG
    Divgi, CR
    McDevitt, MR
    Sgouros, G
    Finn, RD
    Larson, SM
    Scheinberg, DA
    BLOOD, 2002, 100 (11) : 339A - 339A
  • [40] Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia
    Lapusan, Simona
    Vidriales, Maria B.
    Thomas, Xavier
    de Botton, Stephane
    Vekhoff, Anne
    Tang, Ruoping
    Dumontet, Charles
    Morariu-Zamfir, Rodica
    Lambert, John M.
    Ozoux, Marie-Laure
    Poncelet, Philippe
    San Miguel, Jesus F.
    Legrand, Ollivier
    DeAngelo, Daniel J.
    Giles, Francis J.
    Marie, Jean-Pierre
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1121 - 1131
12345